ArticleCancer biology & therapy2018

Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent.

Wan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.